Table 2.
Analysis of cancer/testicular genes expression in melanoma and STBS cells
| Quantitative CTA expression level, median, Q1–Q3, min–max | |||
|---|---|---|---|
| Gene | Melanoma cells | Soft tissues and bones sarcoma cells | U-Mann–Whitney test, p-value (adjusted p-value) |
| GAGE |
2.05 0–0.73–3.33–6.24 |
0 0–0–1.20–3.94 |
< 0.001 (<0.001) |
| HAGE |
0 0–0–0–0.07 |
0 0–0–0–2.37 |
– |
| NY-ESO1 |
2.97 0–1.20–3.93–7.36 |
0 0–0–1.37–5.13 |
< 0.001 (0.003) |
| MAGEA1 |
1.86 0–0.69–3.27–4.49 |
0 0–0–0.61–4.06 |
< 0.001 (< 0.001) |
| PASD1 |
0.60 0–0.05–1.59–2.85 |
0 0–0–0.01–2.78 |
0.002 (0.013) |
| SCP1 |
0 0–0–0–0 |
0 0–0–0–0 |
– |
| SEMG1 |
0 0–0–0–1.18 |
0 0–0–0–0 |
– |
| SLLP1 |
0.02 0–0–0.09–2.69 |
0 0–0–0.01–1.07 |
0.049 (0.113) |
| SPANXA1 |
0 0–0–0–1.06 |
0 0–0–0–0 |
– |
| SSX1 |
0 0–0–0.01–4.50 |
0 0–0–0.01–9.31 |
0.837 (0.887) |
| PRAME |
4.86 2.27–4.06–5.53–6.40 |
0.01 0–0–2.11–2.73 |
< 0.001 (< 0.001) |
| The incidence of gene expression of the CTA | ||||
|---|---|---|---|---|
| Gene | Positive cases/total (positive %) | Fisher’ exact test, p-value (adjusted p-value) | Odds ratio (STBS/melanoma) | |
| Melanoma cells | Soft tissues and bones sarcoma cells | |||
| GAGE | 21/22 (95.5%) | 10/27 (37.04%) | < 0.001 (< 0.001) | 0.028 |
| HAGE | 1/22 (4.54%) | 5/27 (18.52%) | – | 4.773 |
| NY-ESO1 | 21/22 (95.54%) | 15/27 (55.56%) | 0.003 (0.014) | 0.060 |
| MAGEA1 | 20/22 (90.90%) | 10/27 (37.04%) | < 0.001 (0.001) | 0.059 |
| PASD1 | 17/22 (77.28%) | 11/27 (40.74%) | 0.019 (0.061) | 0.202 |
| SCP1 | 0/22 (0%) | 0/27 (0%) | – | – |
| SEMG1 | 3/22 (13.63%) | 0/27 (0%) | – | 0 |
| SLLP1 | 13/22 (59.10%) | 8/27 (29.63%) | 0.048 (0.113) | 0.292 |
| SPANXA1 | 2/22 (9.09%) | 0/27 (0%) | – | 0 |
| SSX1 | 10/22 (45.45%) | 14/27 (51.85%) | 0.776 (0.873) | 1.292 |
| PRAME | 22/22 (100%) | 14/27 (51.85%) | < 0.001 (0.001) | 0 |
CTA expression levels were standardized with log1p function with logarithm’s base equals
Statistically significant values are in italic